Le Lézard
Classified in: Health, Science and technology

ZIVO Bioscience, Inc. Executes Definitive Agreement With NutriQuest, Commences Poultry Field Trial

KEEGO HARBOR, Mich., April 26, 2017 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a company dedicated to the development and commercialization of nutritional compounds and bioactive molecules derived from its proprietary algal strains, announces today that the Company has executed a definitive agreement with NutriQuest®, an innovative leader in animal health and nutrition solutions, to jointly test and develop animal nutrition products for livestock and poultry. The definitive agreement also grants NutriQuest a worldwide license to market the resulting products under its brand name. The first step, a broiler study to begin understanding the full potential value of ZIVO biomass as a feed ingredient, is already underway.

This joint product initiative helps speed ZIVO's entry into global markets and significantly enhances adoption of any new products emanating from the joint effort. NutriQuest has built a successful solutions-oriented practice with global reach, providing the credibility and market visibility that a well-established brand name in animal health and nutrition can command. ZIVO continues to ramp up production of algal biomass to meet the needs of the joint effort and related compliance requirements, such as the months-long product stability study which commenced in mid-February.

About NutriQuest®

NutriQuest® is a team of industry-leading animal experts serving producers by delivering targeted breakthrough solutions. NutriQuest is privileged to have a leadership role in the animal industry and driven by a strong sense of stewardship for animal production. Through collaboration with industry participants, technology providers and customers, NutriQuest is continually working on behalf of animal producers to fill critical needs and provide a high level of value.

With a large US swine customer base and growth in the poultry, ruminant and international sectors, the NutriQuest portfolio of solutions includes research-based feed additives, protein technologies, nutritional monitoring services, water quality products, and humane euthanasia technology, among others that improve performance and cost position to the producer. With world-class internal research capabilities, NutriQuest animal nutrition and production experts scrutinize products and technologies to ensure that all NutriQuest solutions meet or exceed rigorous standards for efficacy, return on investment and practicality.

About ZIVO Bioscience, Inc.

ZIVO Bioscience, Inc. (OTCQB:ZIVO) is a Michigan-based biotech company engaged in the investigation of the health benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

These press releases may also interest you

at 21:00
Atlantic General Hospital ("AGH") is providing notice of an incident that may affect the privacy of information. AGH takes this incident seriously. The following provides details of the incident, AGH's response, and steps individuals may take to...

at 20:30
The "Cataract Surgical Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to  ResearchAndMarkets.com's offering. The global cataract surgical devices market size reached US$ 8.6...

at 20:00
CV Sciences, Inc.  (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release...

at 20:00
Technavio categorizes the global orthopedic soft tissue repair devices market size as estimated to increase by USD 5,633.11 million between 2022 and 2027. The market's growth momentum will be progressing at a CAGR of 11.05% during the forecast...

at 19:30
The "Cardiac Troponin Diagnostics - Forecasts and Opportunities to 2025" report has been added to  ResearchAndMarkets.com's offering. Cardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare...

at 19:23
Healthcare providers at Community Health Center of Snohomish County have won the right to unionize with the Union of American Physicians and Dentists....

News published on 26 april 2017 at 17:03 and distributed by: